Latest Niaspan Stories
MUMBAI, India and BALTIMORE, March 21, 2014 /PRNewswire/ -- Pharma Major Lupin Limited (Lupin) announced today that its US subsidiary, Lupin Pharmaceuticals
ABBOTT PARK, Ill., May 26, 2011 /PRNewswire/ -- The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), today disclosed results from an interim analysis of the AIM-HIGH clinical trial. AIM-HIGH was designed to test whether raising HDL and lowering triglycerides in a patient population with established cardiovascular disease and very well controlled LDL levels could produce an additional 25 percent benefit on cardiovascular outcomes.
ORLANDO, Fla., Nov.
Cortria Corporation today announced the appointment of Gene Cefali, Pharm.D, Ph.D., as Senior Vice President of Clinical Pharmacology and Formulation Development. Dr.
By Ransdell Pierson and Bill Berkrot DALLAS (Reuters) - Plaque shrank in the neck arteries of heart patients taking Kos Pharmaceuticals Inc.'s drug Niaspan along with a statin cholesterol drug, researchers said on Tuesday, suggesting such drug combinations may be able to dramatically lower the incidence of heart disease.
- A serpent whose bite was fabled to produce intense thirst.